Neda Nemat-Gorgani

Neda Nemat-Gorgani

Auto-generated profile, based on publicly available information

Neda Nemat-Gorgani

Department of Radiation Oncology, Stanford University, Stanford, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NBNam Quoc Bui
Nam Quoc Bui
NNNeda Nemat-Gorgani
Neda Nemat-Gorgani
ASAjay Subramanian
Ajay Subramanian
ITIleana A. Torres
Ileana A. Torres
MLMarta Lohman
Marta Lohman
EMEverett J. Moding
Everett J. Moding
Purpose: Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STS), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic responses to immunotherapy. We evaluated circulating tumor DNA (ctDNA) as a biomarker of response in patients treated on a trial combining immunotherapy with local cryotherapy for advanced STS. Patients and Methods: We enrolled 30 patients with unresectable or metastatic STS to a phase II clinical trial. Patients received ipilimumab and nivolumab for four doses followed by nivolumab alone with cryoablation performed between cycles 1 and 2. The primary endpoint was objective response rate (ORR) by 14 weeks. Personalized ctDNA analysis using bespoke panels was performed on blood samples collected prior to each immunotherapy cycle. Results: ctDNA was detected in at least one sample for 96% of patients. Pretreatment ctDNA allele fraction was negatively associated with treatment response, progression-free survival (PFS), and overall survival (OS). ctDNA increased in 90% of patients from pretreatment to postcryotherapy, and patients with a subsequent decrease in ctDNA or undetectable ctDNA after cryotherapy had significantly better PFS. Of the 27 evaluable patients, the ORR was 4% by RECIST and 11% by irRECIST. Median PFS and OS were 2.7 and 12.0 months, respectively. No new safety signals were observed. Conclusions: ctDNA represents a promising biomarker for monitoring response to treatment in patients with advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STS to immunotherapy.

18 March 2016 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
CAClaudia Alicata
Claudia Alicata
Daniela PendeDaniela Pende
Daniela Pende
RMRaffaella Meazza
Raffaella Meazza
PCPaolo Canevali
Paolo Canevali
FLFabrizio Loiacono
Fabrizio Loiacono
MFMichela Falco
Michela Falco
KIR3DL1 is a natural killer (NK) cell receptor that recognizes the Bw4 epitope of human leukocyte antigen (HLA) class I molecules. Following hematopoietic stem cell transplantation for patients lacking Bw4, KIR3DL1‐expressing NK cells from Bw4‐positive donors can be alloreactive and eliminate tumor cells. However, KIR3DL1 alleles having T instead of C at nucleotide 320 (encoding leucine 86 instead of serine 86) are not expressed on the cell surface. Thus, not all individuals testing positive for KIR3DL1 are optimal donors for Bw4‐negative recipients. Therefore, we developed a method for genotyping codon 86, which was validated by its perfect correlation with NK cell phenotype for 100 donors of diverse KIR3DL1/S1 genotype. We typed 600 donors and found that ∼12.2% had the KIR3DL1 gene, but did not express cell‐surface KIR3DL1. By contrast, high‐expressing allotypes were identified when haplotypes from four families with duplicated KIR3DL1/S1 genes were characterized at high resolution. Identifying donors who have KIR3DL1 but lack cell‐surface KIR3DL1 would refine donor selection. With this technique, the number of individuals identified who may not be optimal donors for Bw4‐negative patients increases by threefold, when compared with standard methods. Taken together, we propose that allele typing of killer cell Ig‐like receptor (KIR) polymorphisms should become a standard practice when selecting donors.

14 January 2025 in Cancer Research
Verified
Journal Article
Closed access
EBErik S. Blomain
Erik S. Blomain
SSShaghayegh Soudi
Shaghayegh Soudi
ZWZiwei Wang
Ziwei Wang
ASAnish Somani
Anish Somani
ASAjay Subramanian
Ajay Subramanian
EMEverett J. Moding
Everett J. Moding
Radiotherapy is an integral component in the treatment of many types of cancer, with approximately half of patients with cancer receiving radiotherapy. Systemic therapy applies pressure that can select for resistant tumor subpopulations, underscoring the importance of understanding how radiation impacts tumor evolution to improve treatment outcomes. We integrated temporal genomic profiling of 120 spatially distinct tumor regions from 20 patients with undifferentiated pleomorphic sarcomas (UPS), longitudinal circulating tumor DNA analysis, and evolutionary biology computational pipelines to study UPS evolution during tumorigenesis and in response to radiotherapy. Most unirradiated UPSs displayed initial linear evolution, followed by subsequent branching evolution with distinct mutational processes during early and late development. Metrics of genetic divergence between regions provided evidence of strong selection pressures during UPS development that further increased during radiotherapy. Subclone abundance changed after radiotherapy with subclone contraction tied to alterations in calcium signaling, and inhibiting calcium transporters radiosensitized sarcoma cells. Finally, circulating tumor DNA analysis accurately measured subclone abundance and enabled noninvasive monitoring of subclonal changes. These results demonstrate that radiation exerts selective pressures on UPSs and suggest that targeting radioresistant subclonal populations could improve outcomes after radiotherapy. Significance: Radiotherapy mediates tumor evolution by leading to the expansion of resistant subclonal cancer cell populations, indicating that developing approaches to target resistant subclones will be crucial to improve radiotherapy response.

5 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed polyinosinic: polycytidylic acid (poly I:C)] engages myeloid cells that persist after RT, ultimately enhancing T cell–dependent tumor control. We evaluated BO-112 and hypofractionated RT, with or without nivolumab, in 14 patients with high-risk STS in a phase I neoadjuvant trial. Consistent with its immunologic potency, the triple combination induced rare immune-related adverse events (myositis–myocarditis–myasthenia gravis spectrum), mitigated by BO-112 and nivolumab dose adjustment. BO-112 and RT reprogrammed tumor-associated myeloid cells toward antigen-presenting states, promoted clonal replacement by less exhausted T cells, and enhanced malignant cell depletion compared with standard RT. These immunologic changes coincided with encouraging disease control in a small, high-risk cohort, supporting further clinical development. Significance: Intratumoral BO-112 and hypofractionated RT activate systemic T-cell immunity in mouse models and in a phase I neoadjuvant study of high-risk, resectable sarcoma. Engaging myeloid cells with BO-112 represents a potent strategy with RT to replete T cell–deficient tumors and expand the benefits of neoadjuvant ICB.

2 June 2023
Verified
Other
Open access
NBNam Quoc Bui
Nam Quoc Bui
NNNeda Nemat-Gorgani
Neda Nemat-Gorgani
ASAjay Subramanian
Ajay Subramanian
ITIleana A. Torres
Ileana A. Torres
MLMarta Lohman
Marta Lohman
EMEverett J. Moding
Everett J. Moding
Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis

14 July 2023
Verified
Other
Open access
NBNam Quoc Bui
Nam Quoc Bui
NNNeda Nemat-Gorgani
Neda Nemat-Gorgani
ASAjay Subramanian
Ajay Subramanian
ITIleana A. Torres
Ileana A. Torres
MLMarta Lohman
Marta Lohman
EMEverett J. Moding
Everett J. Moding
Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis